IO Biotech presented Phase 3 clinical trial data at ESMO, showing improvement in PFS for advanced melanoma patients. FDA meeting scheduled for potential Phase 3 trial. Pre-clinical data for pipeline candidates IO112 and IO170 was also presented. The company ended Q3 with $31 million in cash, supporting operations until Q1 2026. Corporate presentations are planned for upcoming healthcare conferences.

In the third quarter of 2025, IO Biotech reported total operating expenses of $19.4 million, with $13.7 million in research and development expenses and $5.6 million in general and administrative expenses. Cash and cash equivalents were $30.7 million as of September 30, 2025. The company expects this cash to support operations through the first quarter of 2026.

Cylembio, IO Biotech’s investigational cancer vaccine candidate, demonstrated improvements in PFS in a Phase 3 trial for advanced melanoma. The company is conducting additional Phase 2 trials for Cylembio in combination with pembrolizumab for lung cancer and head and neck cancer. The company also presented pre-clinical data for pipeline candidates IO112 and IO170 targeting specific factors in the tumor microenvironment.

Investor conferences are planned for November and December 2025, where the company will present its progress and future plans. IO Biotech remains committed to developing novel cancer therapies and bringing them to patients in need as quickly as possible.

IO Biotech is a clinical-stage biopharmaceutical company focused on developing immune-modulatory cancer vaccines. The company’s T-win platform activates T cells to target tumor cells and immune-suppressive cells in the tumor microenvironment. IO Biotech is headquartered in Copenhagen, Denmark, and has US headquarters in New York, NY.

Read more at GlobeNewswire: IO Biotech Reports Third Quarter 2025 Financial Results and